Youxun Medical submitted an A1 prospectus to the Hong Kong Stock Exchange. The sole sponsor is CICC. The company is a platform-based genetic technology company engaged in the development and sale of clinical molecular testing instruments, products and services, including the three business segments of prenatal testing, precision oncology and pathogen testing. The company adopted the “LDT+IVD” dual-track business model and established a portfolio of products and services including 24 commercialized and 14 under development.
The company supports the competitive advantage of products and services in the market through the four core technologies of liquid biopsy, DNA methylation testing, NGS and POCT microfluidic biochips.
The company has a comprehensive product portfolio, and commercial LDT services span different fields, leading technology, and IVD candidate products have entered an advanced stage.
In terms of performance, Youxun Medical recorded revenue of 265.7 million yuan (RMB, same below), 570.8 million yuan and 468.4 million yuan respectively; gross profit was $199.6 million, $217.9 million and $303 million respectively, with gross margins of 75.1%, 38.2% and 64.7% respectively.
The 4 members of the company's management team have an average of more than 15 years of experience in the medical industry, all from leading domestic and foreign pharmaceutical biotechnology companies such as Huada Group, Merck, and top research institutes such as Peking University.
The company's shareholders include senior institutional investors in the field of genetic technology and innovation, such as Huada Co., Ltd., a leader in the NGS sequencing platform industry in China, Decheng Capital, ZGC Science City Ltd., a government guidance fund, Meinian Health, Infinity Capital, Xianfeng Qiyun, and CITIC Guoan, which has a national medical service network.